

INOVIQ EGM and Webinar

Melbourne, Australia, 19 August 2024: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) advises that it will release its financial results for the full year ended 30 June 2024 on Wednesday, 21 August 2024.

On the same day, IIQ is holding its Extraordinary General Meeting (link to [EGM NoM](#)) which is also being broadcast via webinar at 2:30pm. The webinar will provide the opportunity for written questions to be submitted via the platform during the meeting.

The details and link to register for the webinar are provided below:

Date: Wednesday, 21 August 2024
Time: 2:30 PM AEST
Registration: [click the webinar link here](#)

Authorised for release by Company Secretary, Mark Edwards.

- ENDS -

FURTHER INFORMATION

Dr Learne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.